ConductScience.org, home

Paper31316634

Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.

Li J and 5 others. Exp Ther Med, 2019. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials. Papers, record 31316634. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31316634

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.
PubMed
Journal
Exp Ther Med
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
0.39
iCite
Revised in PubMed
2020-10-01
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li JJian
2Wei MMMing-Ming
3Song QQin
4Guo XHXiang-Hua
5Shao LLi
6Liu YYan

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114506197Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.Clin Cancer Res2003https://conductscience.org/library/papers/14506197PubMed
214530779Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.Medicine (Baltimore)2003https://conductscience.org/library/papers/14530779PubMed
315840177Estimating the mean and variance from the median, range, and the size of a sample.BMC Med Res Methodol2005https://conductscience.org/library/papers/15840177PubMed
416630358Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.Arthritis Res Ther2006https://conductscience.org/library/papers/16630358PubMed
516864854Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.J Clin Oncol2006https://conductscience.org/library/papers/16864854PubMed
618305268Systemic lupus erythematosus.N Engl J Med2008https://conductscience.org/library/papers/18305268PubMed
721258803Systemic lupus erythematosus in the elderly.Rheumatol Int2012https://conductscience.org/library/papers/21258803PubMed
822949364Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis.J Zhejiang Univ Sci B2012https://conductscience.org/library/papers/22949364PubMed
922983769Survival analysis of late-onset systemic lupus erythematosus: a cohort study in China.Clin Rheumatol2012https://conductscience.org/library/papers/22983769PubMed
1023083346CD22 and autoimmune disease.Int Rev Immunol2012https://conductscience.org/library/papers/23083346PubMed
1123313811
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.
Ann Rheum Dis2014https://conductscience.org/library/papers/23313811PubMed
1223542611
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
Rheumatology (Oxford)2013https://conductscience.org/library/papers/23542611PubMed
1323553783Epratuzumab for systemic lupus erythematosus.Lupus2013https://conductscience.org/library/papers/23553783PubMed
1423612795Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.Lupus2013https://conductscience.org/library/papers/23612795PubMed
1523821660Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.Blood2013https://conductscience.org/library/papers/23821660PubMed
1624160940Anti-B cell antibody therapies for inflammatory rheumatic diseases.Annu Rev Med2014https://conductscience.org/library/papers/24160940PubMed
1724190520Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.BioDrugs2014https://conductscience.org/library/papers/24190520PubMed
1824212677Association between vitamin D receptor gene BsmI, FokI, ApaI and TaqI polymorphisms and the risk of systemic lupus erythematosus: a meta-analysis.Rheumatol Int2014https://conductscience.org/library/papers/24212677PubMed
1924504808The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry.Arthritis Rheumatol2014https://conductscience.org/library/papers/24504808PubMed
2024773152Epratuzumab for systemic lupus erythematosus.Expert Opin Biol Ther2014https://conductscience.org/library/papers/24773152PubMed

See all 40 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
40533299Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions.Blood Rev2025https://conductscience.org/library/papers/40533299PubMed
39749335CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.Front Immunol2024https://conductscience.org/library/papers/39749335PubMed
38817250A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery.Sci Technol Adv Mater2024https://conductscience.org/library/papers/38817250PubMed
38050332Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus.CPT Pharmacometrics Syst Pharmacol2024https://conductscience.org/library/papers/38050332PubMed
33948430Exploring the role of immunotherapeutic drugs in autoimmune diseases: A comprehensive review.J Oral Biol Craniofac Res2021https://conductscience.org/library/papers/33948430PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD22933PubTator's text mininghttps://conductscience.org/library/genes/933

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31316634

GET https://conductscience.org/api/papers/v1/31316634/references?page=2